Drug Trial Radar · NCT01732913
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Last checked: Nov 19, 2026Latest source record: Nov 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
295
Actual
Start
Jan 16, 2013
Primary completion
May 18, 2016
Study completion May 18, 2016
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Nov 26, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the effect of the addition of idelalisib to rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL). An increased rate of deaths and serious adverse events (SAEs) among participants with front-line chronic lymphocytic leukemia (CLL) and early-line iNHL treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated this study in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA).
Conditions
- Indolent Non-Hodgkin's Lymphomas
Interventions
PlaceboDrug
Tablets administered orally twice daily
RituximabDrug
375 mg/m\^2 administered intravenously weekly for 4 weeks, then every 8 weeks (up to a total of 8 infusions)
IdelalisibDrug
150 mg tablets administered orally twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival
Locations
103 sites in 19 countries. Site status is shown where the registry gives one.
Clearview Cancer Institute
Huntsville, Alabama
Ironwood Cancer and Research Center
Chandler, Arizona
City of Hope Cancer Center
Duarte, California
Saint Jude Heritage Healthcare
Fullerton, California
Pacific Shores Medical Group
Long Beach, California
UCLA Medical Center
Los Angeles, California
Cancer Care Associates
Redondo Beach, California
Cancer Center of Santa Barbara
Santa Barbara, California
Central Coast Medical Oncology Group
Santa Maria, California
Middlesex Hospital Cancer Center
Middletown, Connecticut
Georgetown University Medical Center
Washington D.C., District of Columbia
Florida Cancer Specialists and Research Institute
Fort Myers, Florida
Moffitt Cancer Center
Tampa, Florida
Cancer Center of Kansas
Wichita, Kansas
Wayne State University
Detroit, Michigan
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Icahn School of Medicine at Mount Sinai
New York, New York
Weill Cornell Medical College
New York, New York
Montefiore Medical Center
The Bronx, New York
MetroHealth Medical Center
Cleveland, Ohio
Signal Point Clinical Research Center, LLC
Middletown, Ohio
Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania
Prairie Lakes Healthcare System
Watertown, South Dakota
Tennessee Oncology, PLLC
Chattanooga, Tennessee
Sarah Cannon Cancer Center
Nashville, Tennessee
Texas Oncology, P.A.
Bedford, Texas
Brooke Army Medical Center
Fort Sam Houston, Texas
Center for Cancer and Blood Disorders, PC
Fort Worth, Texas
Shenandoah Oncology Associates, PC
Winchester, Virginia
Virginia Mason Medical Center
Seattle, Washington
Northwest Medical Specialties, PLLC
Tacoma, Washington
Froedtert Hospital and Medical College of Wisconsin
Milwaukee, Wisconsin
Adelaide Cancer Centre
Kurralta Park, Australia
Fiona Stanley Hospital
Murdoch, Australia
Haematology and Oncology Clinics of Australia at Chermside
Milton, Queensland, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Saint Vincent's Hospital
Fitzroy, Victoria, Australia
Western Hospital
Footscray, Victoria, Australia
Royal Perth Hospital
Perth, Western Australia, Australia
Showing 40 of 103 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.